Synergetics Usa Incorporated (NASDAQ:SURG) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research report issued on Tuesday, American Banking & Market News reports. The firm currently has a $4.20 price objective on the stock. Zacks‘ target price would indicate a potential upside of 3.70% from the stock’s previous close.
Shares of Synergetics Usa Incorporated (NASDAQ:SURG) traded up 0.12% on Tuesday, hitting $4.055. 25,735 shares of the company’s stock traded hands. Synergetics Usa Incorporated has a one year low of $2.88 and a one year high of $5.50. The stock has a 50-day moving average of $4.19 and a 200-day moving average of $4.03. The company has a market cap of $100.9 million and a price-to-earnings ratio of 40.50.
Synergetics Usa Incorporated (NASDAQ:SURG) last issued its quarterly earnings data on Tuesday, October 1st. The company reported $0.06 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.06. The company had revenue of $17.90 million for the quarter, compared to the consensus estimate of $17.01 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts predict that Synergetics Usa Incorporated will post $0.19 earnings per share for the current fiscal year.
Synergetics USA, Inc (NASDAQ:SURG) is a medical device company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.